Iovance Biotherapeutics Soars 13.37% on FDA Approval, Buy Rating

Iovance Biotherapeutics Inc. stocks surged by 13.37% in pre-market trading on July 25, 2025, driven by a mix of positive developments and strategic moves within the company.

Iovance Biotherapeutics has recently received FDA approval for its TIL therapy, AMTAGVI (lifileucel), a personalized cell-based immunotherapy. This approval has significantly boosted market confidence and investor sentiment, contributing to the stock's upward trajectory.

H.C. Wainwright reaffirmed its Buy rating for Iovance Biotherapeutics with a $20 price target, citing positive real-world outcomes for AMTAGVI in advanced melanoma cases. The drug showed a 48.8% response rate, particularly effective when administered early, which has further fueled investor optimism.

Iovance has also made strategic hires, appointing Corleen Roche as its new CFO and Marc R. Theoret as the Senior Vice President of regulatory strategies. These appointments are expected to bring fresh insights and enhance the company's operational and financial efficiencies, further bolstering its growth prospects.

Despite recent financial challenges, including negative margins and a free cash flow of approximately -$110M, the company's intellectual assets and promising pipeline of cancer therapies offer a glimmer of hope for future breakthroughs. The market's positive response to these developments suggests that Iovance is poised for significant influence in the biotherapeutic advancements sector.